PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.\', \'Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan. Electronic address: ishikanemasahiro@gmail.com.\', \'Department of Intractable Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.\', \'Department of Refractory Viral Infections, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.\', \'AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.\', \'Department of Respiratory Medicine, Yokohama Sakae Kyosai Hospital, Kanagawa, Japan.\', \'Department of Intractable Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan; Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.\', \'Department of Refractory Viral Infections, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan; Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.\']
?:citedBy
  • -1
?:creator
?:doi
  • S1341-321X(21)00124-010.1016/j.jiac.2021.04.017
?:doi
?:hasPublicationType
?:journal
  • Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
is ?:pmid of
?:pmid
?:pmid
  • 33962861
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
?:title
  • Asymptomatic COVID-19 re-infection in a Japanese male by elevated half-maximal inhibitory concentration (IC50) of neutralizing antibodies.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all